China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$2.83−0.03 (-1.05%)
Close on Nov 18, 2026Market cap $2.71MP/E –Yield –
China SXT Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2026 it was $248.70K, down 32.3% from the year before. The highest annual figure on record is $4.61M in fiscal 2019.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $248.70K | -32.3% |
| FY2025 | Mar 31, 2025 | $367.43K | -33.7% |
| FY2024 | Mar 31, 2024 | $553.97K | +30.0% |
| FY2023 | Mar 31, 2023 | $426.27K | -65.9% |
| FY2022 | Mar 31, 2022 | $1.25M | -55.9% |
| FY2021 | Mar 31, 2021 | $2.84M | +5.0% |
| FY2020 | Mar 31, 2020 | $2.70M | -41.4% |
| FY2019 | Mar 31, 2019 | $4.61M | +35.6% |
| FY2018 | Mar 31, 2018 | $3.40M | +47.1% |
| FY2017 | Mar 31, 2017 | $2.31M | – |
See a number that looks wrong?